Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026)

Scilex Holding (SCLX) posted quarterly Non-Current Deffered Revenue of $1.9 million for Q1 2026, down 16.99% year-over-year from $2.3 million in Q1 2025, and down 4.7% on a QoQ basis from $2.0 million in Q4 2025.

Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Non-Current Deffered Revenue for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Deffered Revenue fell 16.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 16.99% YoY), while the FY2025 annual figure was $2.0 million, down 16.63% from the prior year.
  • Non-Current Deffered Revenue came in at $1.9 million for Q1 2026 at Scilex Holding, down from $2.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $5.2 million in Q1 2022, with the low at $1.9 million in Q1 2026.
  • Average Non-Current Deffered Revenue over 5 years is $3.1 million, with a median of $2.8 million recorded in 2024.
  • Across the five-year window, Non-Current Deffered Revenue changed 0.0% in 2022 and plunged 41.93% in 2023, its largest moves.
  • Year by year, Non-Current Deffered Revenue stood at $3.4 million in 2022, then decreased by 14.53% to $2.9 million in 2023, then dropped by 15.44% to $2.4 million in 2024, then decreased by 16.63% to $2.0 million in 2025, then slipped by 4.7% to $1.9 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.9 million, $2.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn 1.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.95 Mn
Dec 31, 2025 2.04 Mn
Sep 30, 2025 2.14 Mn
Jun 30, 2025 2.24 Mn
Mar 31, 2025 2.34 Mn
Dec 31, 2024 2.45 Mn
Sep 30, 2024 2.56 Mn
Jun 30, 2024 2.67 Mn
Mar 31, 2024 2.78 Mn
Dec 31, 2023 2.90 Mn
Sep 30, 2023 3.01 Mn
Jun 30, 2023 3.14 Mn
Mar 31, 2023 3.26 Mn
Dec 31, 2022 3.39 Mn
Sep 30, 2022 5.19 Mn
Jun 30, 2022 5.19 Mn
Mar 31, 2022 5.19 Mn
Sep 30, 2021 5.19 Mn
Jun 30, 2021 5.19 Mn
Mar 31, 2021 5.19 Mn